These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1371075)

  • 21. The cytoplasmic tail of HIV-1 gp160 contains regions that associate with cellular membranes.
    Haffar OK; Dowbenko DJ; Berman PW
    Virology; 1991 Jan; 180(1):439-41. PubMed ID: 1984664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.
    Cooney EL; McElrath MJ; Corey L; Hu SL; Collier AC; Arditti D; Hoffman M; Coombs RW; Smith GE; Greenberg PD
    Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1882-6. PubMed ID: 8446603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. alpha 1-Acid glycoprotein binds human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein via N-linked glycans.
    Rabehi L; Ferriere F; Saffar L; Gattegno L
    Glycoconj J; 1995 Feb; 12(1):7-16. PubMed ID: 7795416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of endoproteolytic cleavage and intracellular transport of human immunodeficiency virus type 1 envelope glycoproteins using mutant CD4 molecules bearing the transmembrane endoplasmic reticulum retention signal.
    Raja NU; Vincent MJ; Jabbar MA
    J Gen Virol; 1993 Oct; 74 ( Pt 10)():2085-97. PubMed ID: 8409933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV.
    Lederman S; Gulick R; Chess L
    J Immunol; 1989 Aug; 143(4):1149-54. PubMed ID: 2545782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological properties of recombinant HIV envelope synthesized in CHO glycosylation-mutant cell lines.
    Fenouillet E; Miquelis R; Drillien R
    Virology; 1996 Apr; 218(1):224-31. PubMed ID: 8615025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracellular diversion of glycoprotein GP160 of human immunodeficiency virus to lysosomes as a strategy of AIDS gene therapy.
    Lin X; Dashti A; Schinazi RF; Tang J
    FASEB J; 1993 Aug; 7(11):1070-80. PubMed ID: 8370478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients.
    Keefer MC; Bonnez W; Roberts NJ; Dolin R; Reichman RC
    J Infect Dis; 1991 Mar; 163(3):448-53. PubMed ID: 1995718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunization of chimpanzees with recombinant gp160, but not infection with human immunodeficiency virus type 1, induces envelope-specific Th1 memory cells.
    Mannhalter JW; Fischer MB; Wolf HM; Küpcü Z; Barrett N; Dorner F; Eder G; Eibl MM
    J Infect Dis; 1995 Feb; 171(2):437-40. PubMed ID: 7844384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the human immunodeficiency virus type 1 envelope protein interaction with the CD4 host cell receptor.
    Malvoisin E; Wild F
    J Gen Virol; 1994 Apr; 75 ( Pt 4)():839-47. PubMed ID: 8151300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of HIV-1 envelope glycoprotein alters cellular calmodulin.
    Radding W; Pan ZQ; Hunter E; Johnston P; Williams JP; McDonald JM
    Biochem Biophys Res Commun; 1996 Jan; 218(1):192-7. PubMed ID: 8573130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
    Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
    J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
    Kovacs JA; Vasudevachari MB; Easter M; Davey RT; Falloon J; Polis MA; Metcalf JA; Salzman N; Baseler M; Smith GE
    J Clin Invest; 1993 Aug; 92(2):919-28. PubMed ID: 7688766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies.
    Abacioglu YH; Fouts TR; Laman JD; Claassen E; Pincus SH; Moore JP; Roby CA; Kamin-Lewis R; Lewis GK
    AIDS Res Hum Retroviruses; 1994 Apr; 10(4):371-81. PubMed ID: 8068416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The glycosylation of human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) is important for the efficient intracellular transport of the envelope precursor gp160.
    Fenouillet E; Jones IM
    J Gen Virol; 1995 Jun; 76 ( Pt 6)():1509-14. PubMed ID: 7782780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of mutations in constant regions 3 and 4 of envelope of simian immunodeficiency virus.
    Morrison HG; Kirchhoff F; Desrosiers RC
    Virology; 1995 Jul; 210(2):448-55. PubMed ID: 7618279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complement activation by gp160 glycoprotein of HIV-1.
    Thieblemont N; Haeffner-Cavaillon N; Weiss L; Maillet F; Kazatchkine MD
    AIDS Res Hum Retroviruses; 1993 Mar; 9(3):229-33. PubMed ID: 8471312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
    Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intracellular membrane traffic of human immunodeficiency virus type 1 envelope glycoproteins: vpu liberates Golgi-targeted gp160 from CD4-dependent retention in the endoplasmic reticulum.
    Kimura T; Nishikawa M; Ohyama A
    J Biochem; 1994 May; 115(5):1010-20. PubMed ID: 7961587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of a glucosidase inhibitor on the bioactivity and immunoreactivity of human immunodeficiency virus type 1 envelope glycoprotein.
    Fenouillet E; Gluckman JC
    J Gen Virol; 1991 Aug; 72 ( Pt 8)():1919-26. PubMed ID: 1678778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.